Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
featured
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

cancer chemotherapy
lung cancer
osimertinib
kinase inhibitor
EGFR
  • 358 views
  • 08 Dec, 2020
  • 4 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

neutrophil count
pemetrexed
gilbert's syndrome
metastasis
EGFR
  • 0 views
  • 31 Aug, 2021
  • 11 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR

osimertinib
stage iv non-small cell lung cancer
EGFR
lung carcinoma
measurable disease
  • 30 views
  • 19 Sep, 2021
  • 339 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).

cancer chemotherapy
EGFR
lung carcinoma
carboplatin
epidermal growth factor
  • 5 views
  • 17 Sep, 2021
  • 92 locations
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR

  • 0 views
  • 11 Apr, 2021
  • 1 location
Osimertinib In EGFR Mutant Lung Cancer

is: Osimertinib (Tagrisso)

neutrophil count
osimertinib
metastasis
stage iv non-small cell lung cancer
EGFR
  • 3 views
  • 15 May, 2021
TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone

osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. The study will be conducted in 2 phases, a Dose Escalation Phase (Phase 1) and an

cancer chemotherapy
osimertinib
metastasis
kinase inhibitor
kidney function test
  • 0 views
  • 19 Sep, 2021
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with

  • 50 views
  • 15 Mar, 2021
  • 15 locations
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

This is a single arm open-label multi-center phase II study, investigating disease control rate after 3 months of treatment with trastuzumab-emtansine/osimertinib combination therapy in patients

  • 0 views
  • 03 Feb, 2021
  • 5 locations
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management

osimertinib
EGFR
lung carcinoma
bevacizumab
measurable disease
  • 0 views
  • 29 Jul, 2021
  • 1 location